Nuvectis Pharma(NVCT) - 2023 Q4 - Annual Results

Exhibit 99.1 Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights Full Year 2023 Financial Results Cash, and cash equivalents were $19.1 million as of December 31, 2023, compared to $20.0 million as of December 31, 2022. The decrease of $0.9 million was a result of the Company's continued operations, offset primarily by the exercise of warrants issued in our 2022 PIPE transaction. The Company's net loss was $22.3 million for the year ended December 31, 2023, compared to $ ...